Respiratory tract infections: Goals for 1995
Identifieur interne : 002460 ( Main/Exploration ); précédent : 002459; suivant : 002461Respiratory tract infections: Goals for 1995
Auteurs : Theodore C. Eickhoff [États-Unis]Source :
- The American Journal of Medicine [ 0002-9343 ] ; 1985.
English descriptors
- Teeft :
- American journal, Antiviral drugs, Antiviral therapy, Clinical level, Colony hybridization, Core glycolipid, Diagnostic goals, Diagnostic methodology, Diagnostic techniques, Disease burden, Enterotoxigenic escherichia coli, Epithelial cells, Etiologic diagnosis, Explosive growth, Future development, Glycolipid, Greater utilization, Greatest importance, Hospital care, Hybridization, Hybridization studies, Immunotherapy, Infection, Influenza, Influenza vaccine, Influenzae type, Major need, Management table, Medical center, Monoclonal antibodies, Mycoplasmal, Mycoplasmal infection, Next decade, Nursing home, Pneumococcal vaccine, Pneumococcal vaccines, Rapid detection, Rapid diagnosis, Realistic goal, Research laboratories, Respiratory tract infection, Respiratory tract infections, Sputum cultures, Target groups, Target population, Target populations, Therapeutic goals, Tract infection, Tract infections, Upper airways, Vaccine, Viral.
Abstract
Abstract: Goals to be identified for 1995, a decade hence, in the prevention, diagnosis, and management of respiratory tract infections may conveniently be divided into diagnostic goals and goals in therapy and prophylaxis. Major diagnostic goals for bacterial, viral, and mycoplasmal infections of the respiratory tract focus on the development of systems to identify microbial components, such as specific antigens or segments of DNA, using monoclonal antibody techniques or DNA probes for hybridization. Sputum cultures, in the traditional sense, should ultimately become obsolete. Management goals include the development of algorithms to identify patients who should be hospitalized, in contrast to those who can safely be treated on an outpatient basis. New antibiotic drug development should include drugs active against methicillin-resistant staphylococci, broad-spectrum beta-lactam drugs that are orally active against gram-negative bacilli, and drugs that can be used parenterally on a once-daily basis in settings other than the acute care hospital. There are certainly needs to enhance the present spectrum of antiviral drugs and to develop therapeutically useful immunomodulators. There are promising prospects for vaccine development, including live attenuated influenza virus vaccine, parainfluenza virus vaccine, respiratory syncytial virus vaccine, and a Mycoplasma pneumoniae vaccine. With major research support, such vaccines could possibly be fully developed by 1995. Finally, of greatest importance is the need to achieve greater utilization of existing vaccines, that is, inactivated influenza vaccine and the current 23-valent pneumococcal vaccine. A legitimate goal for 1995 would be to achieve 70 percent or greater utilization of these vaccines within the recommended target populations.
Url:
DOI: 10.1016/0002-9343(85)90365-1
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000832
- to stream Istex, to step Curation: 000832
- to stream Istex, to step Checkpoint: 001142
- to stream Main, to step Merge: 002581
- to stream Main, to step Curation: 002460
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Respiratory tract infections: Goals for 1995</title><author><name sortKey="Eickhoff, Theodore C" sort="Eickhoff, Theodore C" uniqKey="Eickhoff T" first="Theodore C." last="Eickhoff">Theodore C. Eickhoff</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DFE40AD5BDDC2DD72F3613F1A76CAC52F8C36F18</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1016/0002-9343(85)90365-1</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-HJMWBRG8-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000832</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000832</idno><idno type="wicri:Area/Istex/Curation">000832</idno><idno type="wicri:Area/Istex/Checkpoint">001142</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001142</idno><idno type="wicri:doubleKey">0002-9343:1985:Eickhoff T:respiratory:tract:infections</idno><idno type="wicri:Area/Main/Merge">002581</idno><idno type="wicri:Area/Main/Curation">002460</idno><idno type="wicri:Area/Main/Exploration">002460</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Respiratory tract infections: Goals for 1995</title><author><name sortKey="Eickhoff, Theodore C" sort="Eickhoff, Theodore C" uniqKey="Eickhoff T" first="Theodore C." last="Eickhoff">Theodore C. Eickhoff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Colorado School of Medicine, and Presbyterian/Saint Luke's Medical Center, Denver, Colorado</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal of Medicine</title><title level="j" type="abbrev">AJM</title><idno type="ISSN">0002-9343</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1985">1985</date><biblScope unit="volume">78</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="supplement">S2</biblScope><biblScope unit="page" from="58">58</biblScope><biblScope unit="page" to="62">62</biblScope></imprint><idno type="ISSN">0002-9343</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-9343</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>American journal</term><term>Antiviral drugs</term><term>Antiviral therapy</term><term>Clinical level</term><term>Colony hybridization</term><term>Core glycolipid</term><term>Diagnostic goals</term><term>Diagnostic methodology</term><term>Diagnostic techniques</term><term>Disease burden</term><term>Enterotoxigenic escherichia coli</term><term>Epithelial cells</term><term>Etiologic diagnosis</term><term>Explosive growth</term><term>Future development</term><term>Glycolipid</term><term>Greater utilization</term><term>Greatest importance</term><term>Hospital care</term><term>Hybridization</term><term>Hybridization studies</term><term>Immunotherapy</term><term>Infection</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenzae type</term><term>Major need</term><term>Management table</term><term>Medical center</term><term>Monoclonal antibodies</term><term>Mycoplasmal</term><term>Mycoplasmal infection</term><term>Next decade</term><term>Nursing home</term><term>Pneumococcal vaccine</term><term>Pneumococcal vaccines</term><term>Rapid detection</term><term>Rapid diagnosis</term><term>Realistic goal</term><term>Research laboratories</term><term>Respiratory tract infection</term><term>Respiratory tract infections</term><term>Sputum cultures</term><term>Target groups</term><term>Target population</term><term>Target populations</term><term>Therapeutic goals</term><term>Tract infection</term><term>Tract infections</term><term>Upper airways</term><term>Vaccine</term><term>Viral</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Goals to be identified for 1995, a decade hence, in the prevention, diagnosis, and management of respiratory tract infections may conveniently be divided into diagnostic goals and goals in therapy and prophylaxis. Major diagnostic goals for bacterial, viral, and mycoplasmal infections of the respiratory tract focus on the development of systems to identify microbial components, such as specific antigens or segments of DNA, using monoclonal antibody techniques or DNA probes for hybridization. Sputum cultures, in the traditional sense, should ultimately become obsolete. Management goals include the development of algorithms to identify patients who should be hospitalized, in contrast to those who can safely be treated on an outpatient basis. New antibiotic drug development should include drugs active against methicillin-resistant staphylococci, broad-spectrum beta-lactam drugs that are orally active against gram-negative bacilli, and drugs that can be used parenterally on a once-daily basis in settings other than the acute care hospital. There are certainly needs to enhance the present spectrum of antiviral drugs and to develop therapeutically useful immunomodulators. There are promising prospects for vaccine development, including live attenuated influenza virus vaccine, parainfluenza virus vaccine, respiratory syncytial virus vaccine, and a Mycoplasma pneumoniae vaccine. With major research support, such vaccines could possibly be fully developed by 1995. Finally, of greatest importance is the need to achieve greater utilization of existing vaccines, that is, inactivated influenza vaccine and the current 23-valent pneumococcal vaccine. A legitimate goal for 1995 would be to achieve 70 percent or greater utilization of these vaccines within the recommended target populations.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Colorado</li></region></list><tree><country name="États-Unis"><region name="Colorado"><name sortKey="Eickhoff, Theodore C" sort="Eickhoff, Theodore C" uniqKey="Eickhoff T" first="Theodore C." last="Eickhoff">Theodore C. Eickhoff</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002460 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002460 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DFE40AD5BDDC2DD72F3613F1A76CAC52F8C36F18
|texte= Respiratory tract infections: Goals for 1995
}}
| This area was generated with Dilib version V0.6.33. |  |